139 related articles for article (PubMed ID: 37351976)
21. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
[TBL] [Abstract][Full Text] [Related]
23. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
24. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
25. Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.
Ouzaid I; Capitanio U; Staehler M; Wood CG; Leibovich BC; Ljungberg B; Van Poppel H; Bensalah K;
Eur Urol Oncol; 2019 Mar; 2(2):141-149. PubMed ID: 31017089
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
27. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
28. A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma.
Kim SH; Park WS; Park B; Pak S; Chung J
Front Oncol; 2019; 9():413. PubMed ID: 31179242
[TBL] [Abstract][Full Text] [Related]
29. The Efficacy of Surgical Metastasectomy for Solitary Metastasis of Renal Cell Carcinoma.
Suzuki K; Hara T; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Urol Int; 2022; 106(4):397-403. PubMed ID: 34134119
[TBL] [Abstract][Full Text] [Related]
30. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment.
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Int; 2007; 79(2):145-51. PubMed ID: 17851285
[TBL] [Abstract][Full Text] [Related]
31. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
32. Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Fluhrer H; Hutterer GC; Golbeck S; Stidl M; Niedrist T; Pichler R; Mischinger J; Seles M; Mannweiler S; Spiegelberg J; Bauernhofer T; Jost PJ; Ahyai S; Zigeuner R; Pichler M; Barth DA
Ther Adv Med Oncol; 2022; 14():17588359221134065. PubMed ID: 36425872
[TBL] [Abstract][Full Text] [Related]
33. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era.
Lyon TD; Thompson RH; Shah PH; Lohse CM; Boorjian SA; Costello BA; Cheville JC; Leibovich BC
J Urol; 2020 Feb; 203(2):275-282. PubMed ID: 31393812
[TBL] [Abstract][Full Text] [Related]
34. Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis.
Palumbo C; Pecoraro A; Knipper S; Rosiello G; Tian Z; Shariat SF; Simeone C; Briganti A; Saad F; Berruti A; Antonelli A; Karakiewicz PI
Anticancer Res; 2019 Aug; 39(8):4357-4361. PubMed ID: 31366530
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes and prognostic factors following the surgical resection of renal cell carcinoma spinal metastases.
Kato S; Demura S; Murakami H; Yoshioka K; Shinmura K; Yokogawa N; Shimizu T; Kawahara N; Tsuchiya H
Cancer Sci; 2021 Jun; 112(6):2416-2425. PubMed ID: 33780597
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy.
Mizuno R; Takamatsu K; Yasumizu Y; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Asanuma H; Mikami S; Oya M
Urol Int; 2022; 106(11):1145-1149. PubMed ID: 35139522
[TBL] [Abstract][Full Text] [Related]
38. [The significance of metastasectomy in patients with metastatic renal cell carcinoma].
Miyata H; Shinohara N; Murahashi N; Tsuchiya K; Miyajima N; Maruyama S; Abe T; Kaga K; Hirano S; Nonomura K
Hinyokika Kiyo; 2015 Feb; 61(2):49-54. PubMed ID: 25812593
[TBL] [Abstract][Full Text] [Related]
39. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
[TBL] [Abstract][Full Text] [Related]
40. Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Maisel F; Smolle MA; Mollnar S; Riedl JM; Barth DA; Seles M; Terbuch A; Rossmann CH; Eisner F; Mannweiler S; Hutterer G; Zigeuner R; Pummer K; Smolle-Jüttner FM; Lindenmann J; Stotz M; Gerger A; Jost PJ; Bauernhofer T; Pichler M; Posch F
Clin Genitourin Cancer; 2022 Aug; 20(4):344-353. PubMed ID: 35443915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
